Research Study
Clairvoyant - Psilocybin Assisted Psychotherapy for Alcohol Use Disorder
Reducing alcohol consumption through psilocybin-assisted psychotherapy
Closed Recruitment
Health Areas
Plant based medicines, Other General Health , Other Men’s Health , Anxiety, Other Mental Health
Study Purpose
This phase 2 clinical trial evaluates the safety and efficacy of psilocybin-assisted psychotherapy in adults with Alcohol Use Disorder (AUD) through analysis of alcohol consumption and symptom severity over the 8-week treatment period as compared to baseline.
Details
The study consists of 13 visits across approximately 29 weeks in a total of 3 periods: Screening Period (up to 5 weeks), Treatment Period (8 weeks) with 2 administration sessions, and a Follow-Up Period (16 weeks). Participation will involve psychotherapy and administration of either psilocybin (25mg) or a placebo. Additionally, participation will involve medical assessment and administration of questionnaires. Remuneration includes $50 for every visit and $100 for each dosing visit.
location
Lower Mainland
recruitment end date
2024-07-10
eligibility
Age: 19 Years - 70 Years Old
Accepting Healthy Volunteers: No
Research Team Information
Principal investigator
Christian Schütz
health authority affiliation
Provincial Health Services Authority
academic affiliation
University of British Columbia - Vancouver
